Latest Articles
Alpenglow Biosciences Announces AACR 2025 Dinner Lecture: "Decoding Endometrial Cancers: A Spatial Biology Odyssey in 2D and 3D" - Yahoo
Alpenglow Biosciences Announces AACR 2025 Dinner Lecture: "Decoding Endometrial Cancers: A Spatial Biology Odyssey in 2D and 3D" Yahoo
Published: April 8, 2025, 2:12 p.m.
Alpenglow Biosciences Announces AACR 2025 Dinner Lecture: "Decoding Endometrial Cancers: A Spatial Biology Odyssey in 2D and 3D" - Business Wire
Alpenglow Biosciences Announces AACR 2025 Dinner Lecture: "Decoding Endometrial Cancers: A Spatial Biology Odyssey in 2D and 3D" Business Wire
Published: April 8, 2025, 2:12 p.m.
Clinical Trial Participation Gaps in Endometrial Cancer - Physician's Weekly
Clinical Trial Participation Gaps in Endometrial Cancer Physician's Weekly
Published: April 8, 2025, 1:53 p.m.
Dual PD-1/CTLA-4 Inhibition With Cadonilimab Plus Lenvatinib Yields Disease Control in Advanced Endometrial Cancer - OncLive
Dual PD-1/CTLA-4 Inhibition With Cadonilimab Plus Lenvatinib Yields Disease Control in Advanced Endometrial Cancer OncLive
Published: April 8, 2025, 1:11 p.m.
Enhancing Preoperative Diagnostic Accuracy in Endometrial Hyperplasia: A Comparison of Biopsy Methods - Cureus
Enhancing Preoperative Diagnostic Accuracy in Endometrial Hyperplasia: A Comparison of Biopsy Methods Cureus
Published: April 8, 2025, 12:01 p.m.
Enhancing Preoperative Diagnostic Accuracy in Endometrial Hyperplasia: A Comparison of Biopsy Methods - The Cureus Journal of Medical Science
Enhancing Preoperative Diagnostic Accuracy in Endometrial Hyperplasia: A Comparison of Biopsy Methods The Cureus Journal of Medical Science
Published: April 8, 2025, 12:01 p.m.
Neoadjuvant Nivolumab Appears Effective for Resectable, dMMR Endometrial Cancer - Oncology Nurse Advisor
Neoadjuvant Nivolumab Appears Effective for Resectable, dMMR Endometrial Cancer Oncology Nurse Advisor
Published: April 8, 2025, 4 a.m.
Follow-up of hereditary endometrial carcinoma caused by MLH3 gene mutation: a case report - Frontiers
Follow-up of hereditary endometrial carcinoma caused by MLH3 gene mutation: a case report Frontiers
Published: April 7, 2025, 3:32 p.m.
Sexual dysfunction and quality of life in cervical and endometrial cancer patients before and after low-dose-rate brachytherapy: a cohort study - Frontiers
Sexual dysfunction and quality of life in cervical and endometrial cancer patients before and after low-dose-rate brachytherapy: a cohort study Frontiers
Published: April 4, 2025, 8:35 p.m.
Endometrial Cancer Treatment Market 2034: Clinical Trials, - openPR.com
Endometrial Cancer Treatment Market 2034: Clinical Trials, openPR.com
Published: April 4, 2025, 4:30 a.m.
Link copied to clipboard!